E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic Genotype 2 or 3 HCV Infection |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10019744 |
E.1.2 | Term | Hepatitis C |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10008912 |
E.1.2 | Term | Chronic hepatitis C |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objectives of this study are:
• To determine the efficacy of treatment with GS-7977+ ribavirin (RBV) as measured by the proportion of subjects with sustained viral response 12 weeks after discontinuation of therapy (SVR12)
• To assess the safety and tolerability of GS-7977+RBV as measured by review of the accumulated safety data |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this study are:
• To determine the proportion of subjects who attain SVR at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)
• To determine the efficacy of treatment with GS-7977+RBV based on prior treatment history
• To evaluate the kinetics of circulating HCV RNA during treatment and after treatment discontinuation
• To evaluate the emergence of viral resistance to GS-7977 during treatment and after treatment discontinuation |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Pharmacogenomic Substudy:
All subjects will be eligible to participate in the Pharmacogenomic Substudy. A blood sample should be drawn at the Baseline/Day 1 visit if consent is obtained for this Substudy. If not obtained at Baseline/Day 1, the sample may be drawn at any time during the study. |
|
E.3 | Principal inclusion criteria |
1. Willing and able to provide written informed consent
2. Male or female, age ≥ 18 years
3. Confirmation of chronic HCV infection
4. Classification as treatment naïve or treatment experienced
5. Cirrhosis determination (approximately 20% of subjects may have cirrhosis)
6. Liver imaging within 6 months of Baseline/Day 1 (required in cirrhotic patients only, to exclude hepatocellular carcinoma)
7. Infection with HCV genotype 2 or 3 as determined at Screening
8. HCV RNA ≥ 10e4 IU/mL at Screening
9. Body mass index (BMI) ≥ 18 kg/m2
10. Screening ECG without clinically significant abnormalities |
|
E.4 | Principal exclusion criteria |
1. Prior exposure to a direct-acting antiviral targeting the HCV NS5B polymerase
2. Pregnant or nursing female or male with pregnant female partner
3. Chronic liver disease of a non-HCV etiology
4. Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)
5. Contraindication to RBV therapy
6. History of malignancy diagnosed or treated within 5 years; subjects under evaluation for malignancy are not eligible
7. History of clinically significant hemoglobinopathy
8. Chronic use of systemically administered immunosuppressive agents
9. Clinically-relevant drug or alcohol abuse within 12 months of screening.
10. History of solid organ transplantation
11. Current or prior history of clinical hepatic decompensation |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint is SVR12 (HCV RNA <LLOQ 12 weeks after cessation of therapy). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
12 weeks after cessation of therapy. |
|
E.5.2 | Secondary end point(s) |
Secondary efficacy endpoints include the proportion of subjects with HCV RNA < LLOQ at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24); viral breakthrough; and relapse. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
4 and 24 weeks after cessation of therapy. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| Information not present in EudraCT |
E.8.4 | The trial involves multiple sites in the Member State concerned | Information not present in EudraCT |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 80 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |